Chromatrap reports benefits of ChIP technology in ground breaking research

Chromatrap reports on 3 further customer papers published in different prestigious peer reviewed journals, which cite how its proprietary solid state Chromatin Immunoprecipitation (ChIP) technology has enabled ground breaking research.

A recent study published in Drug Metabolism & Deposition looks at the role of Chromatin structural changes in regulating human CYP3A ontogeny.

This paper found that variable trajectories in the development of drug metabolizing enzymes contributed to differences between individuals in their susceptibility to chemical toxicity and adverse reaction to drugs, particularly in the early stages of life. The paper looks at the currently unknown factors linked to these inter-individual differences that may be involved. By looking at the discerned CYP3A4 and 3A7 regulatory domains in individuals of various ages, histone modifications can be used to research the structural dynamics of chromatin as elucidated using Chromatrap ChIP kits.

Results of research published in the Journal of Immunology review how 'Moderate alcohol induces stress proteins HSF1 and hsp70 and inhibits pro-inflammatory cytokines resulting in endotoxin tolerance'. Researchers discuss how binge or moderate alcohol exposure leads to impaired host defences against infection. This susceptibility is shown to be due to compromised innate immune response. The study probes the molecular mechanism by which alcohol mediates this immunosuppression, but reaches no firm conclusion. The Department of Medicine, University of Massachusetts Medical School show in this paper the mechanistic role that cellular stress proteins HSF1 and hsp70 play in alcohol-mediated inhibition of the TLR4/MyD88 pathway.

A third paper, published in Biochim Biophys Acta, discusses the results of research by the Center for Molecular Medicine at Xiangya Hospital in China who were studying 'FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells'. Studying prostate cancer cells (PCa) the team looked at regulation of E2F and AR (androgen receptor) in the transcription of CDC6, a key component of the DNA replication initiation machinery. FOXM1 which is a cell proliferation specific transcription factor, stimulated CDC6 transcription in cooperation with AR, in addition to having an effect on the E2F pathway. Both overexpression and knockdown approaches were used.

Launched worldwide in 2012 - Chromatrap® solid-state ChIP technology has been shown by a growing number of research groups worldwide to be more efficient than conventional bead-based methods. This is because the solid phase porous polymer, functionalized with either protein A or G, provides a greater surface area for chromatin antibody binding with very low non-specific binding. In addition, it uses a spin column approach, offering significant speed, process and carry-over advantages over sepharose or magnetic beads. DNA pull down with Chromatrap® is up to 25 times more than conventional methods, whilst the signal to noise ratio for DNA enrichment is 2 to 3 times better, even with low chromatin samples between 50ng to 3000ng per immunoprecipitation.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chromatrap® - Porvair Sciences Ltd. (2019, June 20). Chromatrap reports benefits of ChIP technology in ground breaking research. News-Medical. Retrieved on October 27, 2020 from https://www.news-medical.net/news/20160712/Chromatrap-reports-benefits-of-ChIP-technology-in-ground-breaking-research.aspx.

  • MLA

    Chromatrap® - Porvair Sciences Ltd. "Chromatrap reports benefits of ChIP technology in ground breaking research". News-Medical. 27 October 2020. <https://www.news-medical.net/news/20160712/Chromatrap-reports-benefits-of-ChIP-technology-in-ground-breaking-research.aspx>.

  • Chicago

    Chromatrap® - Porvair Sciences Ltd. "Chromatrap reports benefits of ChIP technology in ground breaking research". News-Medical. https://www.news-medical.net/news/20160712/Chromatrap-reports-benefits-of-ChIP-technology-in-ground-breaking-research.aspx. (accessed October 27, 2020).

  • Harvard

    Chromatrap® - Porvair Sciences Ltd. 2019. Chromatrap reports benefits of ChIP technology in ground breaking research. News-Medical, viewed 27 October 2020, https://www.news-medical.net/news/20160712/Chromatrap-reports-benefits-of-ChIP-technology-in-ground-breaking-research.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Disrupting ChIP Assay Technology with New Advancements